Showing 3161-3180 of 8875 for: Cochrane Systematic Reviews Back
- Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum
Cochrane Systematic Reviews, 16-Mar-2011
Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by systemic intravascular activation of coagulation. There are several obstetric causes of DIC during pregnancy and postpartum.
- Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease
Cochrane Systematic Reviews, 14-May-2015
Convective dialysis modalities (haemofiltration (HF), haemodiafiltration (HDF), and acetate-free biofiltration (AFB)) removed excess body fluid across the dialysis membrane with positive pressure and accumulated middle- and larger-size accumulated solutes
- Haemodilution for acute ischaemic stroke
Cochrane Systematic Reviews, 27-Aug-2014
Ischaemic stroke interrupts the flow of blood to part of the brain. Haemodilution is thought to improve the flow of blood to the affected areas of the brain and thus reduce infarct size.
- Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
Cochrane Systematic Reviews, 13-Jan-2010
Anaemia affects 60% to 80% of patients with chronic kidney disease (CKD) reduces quality of life and is a risk factor for early death. Treatment options are blood transfusion, erythropoietin (EPO) and darbepoetin alfa. Recently higher haemoglobin (Hb) and
- Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 19-Jun-2017
Chronic bronchitis and chronic obstructive pulmonary disease (COPD) are serious conditions in which patients are predisposed to viral and bacterial infections resulting in potentially fatal acute exacerbations. Chronic obstructive pulmonary disease is def
- Haemostatic drugs for traumatic brain injury
Cochrane Systematic Reviews, 13-May-2015
Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial bleeding is a common complication of TBI, and intracranial bleeding can develop or worsen after hospital admission. Haemostatic drugs may reduce the occurrence or size o
- Haemostatic therapies for acute spontaneous intracerebral haemorrhage
Cochrane Systematic Reviews, 17-Apr-2018
Outcome after spontaneous (non-traumatic) intracerebral haemorrhage (ICH) is influenced by haematoma volume; up to one-third of ICHs enlarge within 24 hours of onset. Early haemostatic therapy might improve outcome by limiting haematoma growth. This is an
- Haloperidol alone or in combination for acute mania
Cochrane Systematic Reviews, 12-May-2009
The main objectives in treating mania are to control dangerous behaviour, reduce suicide, produce appropriate acute sedation and shorten the episode of mood disturbance. Among different drugs, haloperidol has for many years been used in treating psychotic
- Haloperidol discontinuation for people with schizophrenia
Cochrane Systematic Reviews, 21-Apr-2019
Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol
- Haloperidol dose for the acute phase of schizophrenia
Cochrane Systematic Reviews, 7-Aug-2013
Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged.
- Haloperidol for agitation in dementia
Cochrane Systematic Reviews, 12-Apr-2012
Agitation occurs in up to 70% of demented patients. Haloperidol has been used for decades to control agitation in dementia, but its effectiveness remains unclear. Previous meta-analyses examined only English language publications or compared haloperidol w
- Haloperidol for long‐term aggression in psychosis
Cochrane Systematic Reviews, 27-Nov-2016
Psychotic disorders can lead some people to become agitated. Characterised by restlessness, excitability and irritability, this can result in verbal and physically aggressive behaviour - and both can be prolonged. Aggression within the psychiatric setting
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation)
Cochrane Systematic Reviews, 31-Jul-2017
Haloperidol used alone is recommended to help calm situations of aggression or agitation for people with psychosis. It is widely accessible and may be the only antipsychotic medication available in limited-resource areas.
- Haloperidol for the treatment of nausea and vomiting in palliative care patients
Cochrane Systematic Reviews, 2-Nov-2015
Nausea and vomiting are common symptoms in patients with terminal, incurable illnesses. Both nausea and vomiting can be distressing. Haloperidol is commonly prescribed to relieve these symptoms. This is an updated version of the original Cochrane review p
- Haloperidol plus promethazine for psychosis‐induced aggression
Cochrane Systematic Reviews, 25-Nov-2016
Health services often manage agitated or violent people, and such behaviour is particularly prevalent in emergency psychiatric services (10%). The drugs used in such situations should ensure that the person becomes calm swiftly and safely.
- Haloperidol versus chlorpromazine for schizophrenia
Cochrane Systematic Reviews, 31-Jan-2013
Chlorpromazine and haloperidol are benchmark antipsychotic drugs. Both are said to be equally effective when used at equivalent doses, but have different side-effect profiles.
- Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
Cochrane Systematic Reviews, 12-Jan-2015
Haloperidol is worldwide one of the most frequently used antipsychotic drugs with a very high market share. Previous narrative, unsystematic reviews found no differences in terms of efficacy between the various first-generation (“conventional”, "typical")
- Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia
Cochrane Systematic Reviews, 12-Jun-2014
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low-potency antipsychotic drugs are often clinically perceived as less efficacious t
- Haloperidol versus placebo for schizophrenia
Cochrane Systematic Reviews, 5-Nov-2013
Haloperidol was developed in the late 1950s for use in the field of anaesthesia. Research subsequently demonstrated effects on hallucinations, delusions, aggressiveness, impulsiveness and states of excitement and led to the introduction of haloperidol as
- Hand and ultrasonic instrumentation for orthograde root canal treatment of permanent teeth
Cochrane Systematic Reviews, 7-Feb-2019
Endodontic treatment of root canals or root canal treatment is a frequently performed dental procedure and is carried out on teeth in which irreversible pulpitis has led to necrosis (death) of the dental pulp (nerve). Removal of the necrotic tissue remnan
